To determine if the reduction of intratumoral transgene-specific CD8+ T cells shown in Fig. 2 was biologically relevant, an ex vivo cytotoxicity assay was performed using B16-F10 melanoma cells as targets (Fig. 3). The gene discussed is CD8A; the disease is melanoma.